TB-500 vs BPC-157
Side-by-side comparison of TB-500, BPC-157 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | TB-500 Thymosin Beta-4 Synthetic Analogue Recovery | BPC-157 Body Protection Compound-157 Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Thymic Peptide Analogue | Gastric Pentadecapeptide |
| Amino acids | 43 | 15 |
| Molecular weight | 4,921 Da | 1,419.5 Da |
| Half-life | Long-acting (days) | ~4 hrs (SC) |
| Route(s) | Subcutaneous, Intramuscular | Subcutaneous, Intramuscular, Oral (research only) |
| Mechanism & Research | ||
| Primary mechanism | TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical … | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… |
| Research status | Research Compound | Research Compound |
| Evidence summary | TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been … | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… |
| Protocol & Dosing | ||
| Typical dose | 5–10 mg per injection | 200–500 mcg per injection |
| Frequency | 2x per week (loading), then weekly | Once or twice daily |
| Duration | 4–8 weeks | 4–12 weeks |
| Timing | No specific timing requirement | Near injury site when possible |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S0) |
| Deeper reading | ||
| Related peptides | BPC-157, GHK-Cu, Thymosin Alpha-1 | TB-500, GHK-Cu, KPV, Pentadeca Arginate |
| Full profile | Read full TB-500 profile → | Read full BPC-157 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.